PATENT

ATTORNEY DOCKET NO.: 044574-5098 US

$_{1\%}$ $^{1~8}$ 2002 In the united state	ES PATENT AND TRADEMARK OFFICE
pplication of:)
Dario C. ALTIERI et al.)
Application No.: 10/042,302) Group Art Unit: 1636
Filed: January 11, 2002)) Examiner: Unassigned
For: Detection of Survivin in the)
Biological Fluids of Cancer Patients)
Commissioner for Patents	,

Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Attached is a PCT International Search Report dated September 23, 2002 listing the cited documents. Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

RECEIVED

NOV 1 9 2002

TECH CENTER 1600/2900

ATTORNEY DOCKET NO. 044574-5098-US

Application No.: 10/042,302

Page 2

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. § 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

Melenel 87mm Michael S. Tusaw Rex No. 43,20

Sally P. Teng Reg. No. 45,397

Dated: November 18, 2002

MORGAN, LEWIS & BOCKIUS LLP

CUSTOMER NO.: 009629

1111 Pennsylvania Avenue, NW

Washington, D.C. 20004 Telephone: (202) 739-3000

Facsimile: (202) 739-3001

SPT:mk

INFORMA	ON DISCLOSUR	E CITATION	Attorney Docket 044574-5098-US		Application No. 10/042,302		
(Uses veral sheets if necessary) PTO Form 1449		Applicants: Dario C. ALTIERI et al. Page 1 of 1					
NOV 18 2002 age: November	PTO Form 1449	,	Filing Date: January 11		oup: Unassign	ned	
	7 2002	U.S. PAT	ENT DOCUMENTS		"		
initial areas	Patent No.	Date	Name	Class	SubClass	Filing Dat	
		FOREIGN P	ATENT DOCUMENTS				
	Document No.	Date	Country	Class	SubClass	Translatio	
	98/22589	05/1998	WIPO				
	01/53535 A2	07/2001	WIPO				
					<u> </u>		
			ng Author, Title, Date, Pe				
			ptosis gene, <i>survivin,</i> expust 1997, pp. 917-921	pressed in ca	incer and lyn	nphoma",	
	Jouben-Steele, et al.	"Survivin Expr	ression in the Surveilland	ce of Urothe	lial Neoplasi	a", Laborato	
	Investigation, Unite	d States and Car	nadian Academy of Patho	ology, vol. 1	, no. 79, Jan	uary 1999, p	
	99A, AN569, abstra		1 Diamania a CDIa da	dan Camaan''	Jaymal of I	nauronaa	
	Moore, "Urine Dete Medicine, vol. 33, n		n and Diagnosis of Blade 01, pp. 202-203	uer Cancer,	Journal of II	nsurance	
	Sarela, et al., "Expre	ession of the anti	iapoptosis gene, Survivir	i, predicts de	eath from rec	urrent	
			no. 5, May 2000, pp. 64				
	Smith, et al., "Urine Medical Association	Detection of Sun, Jan. 17, 2001,	rvivin and Diagnosis of vol. 285, no. 3, pp. 324-	Bladder Car 328, XP008	ncer", Journa 003639, ISS	1 of Americ: N: 0098-748	
				• • • • • • • • • • • • • • • • • • • •	-		
<u> </u>							
					-		
-							
						-	
	<u> </u>						
							
				RE	CEIVE	D	
				210	V 1 9 2007		
				МО,	V 1 9 50m		
				TECH C	NTER 1600	/2900 -	
-							
xaminer			Date Cor	nsidered			
	if reference considered	whether or not ci	itation is in conformance w		9: draw line th	rough citatio	
			form with next communic				